BioSante Pharmaceuticals, Inc. (BPAX)

[Just the facts maam]

In order to assess what impact an NDA submission may have on BPAX share price I have collected the following information.

COMPANIES WITH PENDING NDA SUBMISSIONS.

Arena Pharmaceuticals - MC = $ 1.1 Billion
Revenue $ 12.72 M Net Income (-$109.22 M)
Lorcaserin (weight management) - Resubmitted NDA
Pulmonary arterial hypertension Phase 1
Arena pipeline

Amarin Corp. MC $1.59 billion
Revenue $0 Net Income (-$69.13 M)
No approved products
NDA : AMR101: Under Investigation for Hypertriglyceridemia and Mixed Dyslipidemia (multiple lipid disorders) and for Reducing Cardiovascular Risk
Amarin Corp pipeline

Vivus MC $ 2.45 B
Revenue $0 Net Income (-$47.03 M)
One approved drug for Erectile Disfunction STENDRA
Qnexa weight-loss therapy targeting obesity PDUFA date extension: July 17 2012
Qnexa® may be the first therapy to address Type 2 diabetes as well as weight loss Phase 2 Trial
Qnexa A phase 2 study (OB-204) evaluating the safety and efficacy for the treatment of obstructive sleep apnea
Vivus Pipeline


BUYOUT VALUE

Micro Met bout out by Amgem for $1.16 Billion
Revenue $ 21.92 M Net Income (– $74.16 M)
Blinatumomab, a BiTE antibody that has demonstrated encouraging single-agent activity in both adult and pediatric patients with ALL as well as adult patients with NHL, and is currently under investigation in five trials:
Two Phase 2 trials for adult patients with relapsed/refractory ALL
Phase 1/2 trial for pediatric patients with relapsed/refractory ALL
Phase 2 trial for adult ALL patients with minimal residual disease (MRD)
Phase 1 trial for adult patients with relapsed/refractory NHL



Ardea Bioscience To be acquired by AsraZeneca for $1.26 Billion
Revenue $ 7.3 M Net Income (– $86.58 M)
Gout Phase 2 trial
Gout Phase 1 trial
Liver Cancer Phase 2 trial
Liver Cancer Phase 1 trail
Ardea Pipeline

Inhibitex - Acquired by Bristol-Myers Squibb for $2.5 Billion
Revenue $1.6 M Net Income (–$ 22.67M)
Hepatitis C Phase 2 trial
Shingles Phase 2 trial
Aurexis®, a humanized monoclonal antibody Phase 2
Staph vaccine Phase 2
Inhibitex pipeline


Pharmasset acquired by Gilead for $11 Billion
Three promising mid- to late-stage hepatitis C drugs
It has seven candidates in its pipeline: four compounds in Phase 2 and three in Phase 1.at the time of the sale


Honorable mention
Human genome Science Inc. MC $2.71 Billion turned down a $2.6 B offer from GSK
Revenue $130.98 m Net Income (-$381.11 million)
BENLYSTA® became the first new approved drug for lupus in more than fifty years
Raxibacumab -new way to address the threat of inhalation anthrax. Phase 3 trial
Phase 3 clinical trials of darapladib in men and women with chronic coronary heart disease through GSK
Albiglutide in patients with type 2 diabetes mellitus through GSK.









Companies with no approved drug going into phase three.

Pharmacyclics, Inc MC $2.26 Billion
Has a cancer program with a number of phase 1 and 2 trials underway of which a Leukememia trial is about start a phase 3 trial.
Revenue 8.3 Million Net Income (-35.20)